Highest-materiality recent filing
Quantum Cyber signs definitive agreements to acquire Bridgeport manufacturing facility for $3.2M
Subsidiary Quantum Drones Corp. to acquire real property and installed equipment at 38 Union Ave, Bridgeport, CT for $3.2M aggregate consideration.
Dismissed Reliant CPA PC effective June 22, 2026; Haskell & White LLP appointed as independent auditor for FY 2026.
Consideration: $1M cash plus $5M in restricted shares, vesting over eight quarters with six-month lock-up.
Quantum Cyber pivots from biotech to defense AI and quantum autonomous systems
Changed name from Mainz Biomed to Quantum Cyber N.V.; ticker changed to QUCY.
Quantum Cyber licenses drone/cyber IP from BP United for $5M cash and 20M shares
Exclusive, perpetual, worldwide license to BP United's IP (patents, trademarks, know-how) for drones and cyber applications.
Quantum Cyber increases equity distribution capacity to $100M; CFO Caragol moves to consulting role
Equity distribution agreement amended; offering amount increased from $10M to $100M.
Second closing on Apr 22, 2026: issued Series D/E preferred convertible into up to 225M ordinary shares each, representing >90% fully diluted shares.
Mainz Biomed sells next-gen CRC screening IP for $1.25M, updates Nasdaq equity compliance
Entered asset purchase agreement to sell Next Gen IP for $1.25M; closing by April 23, 2026.
Nasdaq notified Mainz Biomed on Mar 20, 2026 that its share price closed below $1.00 for 30 consecutive business days through Mar 19, 2026.
Quantum Cyber pre-funded $3M by David Lazar; targets acquisitions in quantum & cyber defense
David Lazar pre-funded $3M second tranche; total investment now $6M.
Mainz Biomed appoints cyber security veteran Robert Liscouski as Chairman; ticker changes to QUCY
Robert P. Liscouski appointed Chairman effective March 11, 2026; election to be ratified at April 2026 EGM.
Mainz Biomed secures $6M private placement, names David Lazar Chairman; pivots to pancreatic cancer
First tranche of $3M closed Feb 13; second $3M expected after shareholder approval by April 15, 2026.
Mainz Biomed raises $2.15M via ATM equity offering; fully utilizes prospectus supplement
Sold 1,735,194 ordinary shares at prevailing market prices for gross proceeds of $2,152,822.40.
Effective as of May 13, 2026, to fill vacancy in the composition of the Board of Directors (the “Board”), the Board of the Company appointed Peter O’Rourke to serve as a director
On May 4, 2026, the Company entered into a Consulting Agreement with William Caragol, the Chief Financial Officer of the Company (the “Caragol Consulting Agreement”), effective as of April 22, 2026
On April 22, 2026, our shareholders approved at an Extraordinary General Meeting the appointment of David Natan and Avraham Ben-Tzvi to our board of directors, and Mr. Natan and Mr. Ben-Tzvi became directors of our company.
On April 22, 2026, our shareholders approved at an Extraordinary General Meeting the appointment of David Natan and Avraham Ben-Tzvi to our board of directors, and Mr. Natan and Mr. Ben-Tzvi became directors of our company.
Max materiality 0.90 · Median 0.65 · Most common event other_material